[
ABSTRAKKanker Nasofaring (KNF) salah satu pilihan terapinya adalah
kemoterapi neoajuvan. Respon kemoterapi ini, di pengaruhi oleh Epidermal Growth
Factor Receptor(EGFR), faktor yang berperan pada pertumbuhan dan invasif tumor.
Tujuan dari penelitian ini adalah untuk mengetahui perbandingan tingkat ekspresi
EGFR dengan respon kemoterapi neoajuvan dan tingkat ekstensif tumor primer.
Penelitian ini merupakan studi potong lintang deskriptif, dilakukan penilaian respon
kemoterapi neoajuvan dan tingkat ekstensif tumor primer, pada pasien KNF yang telah
mendapat kemoterapi dan dilakukan pemeriksaan ekspresi EGFR. Hasil penelitian:
Proporsi ekspresi EGFR pada kanker nasofaring untuk ekspresi negatif, positif dan
kuat, berturut-turut sebesar (10%), (70%) dan (20%). Pasien yang respon terhadap
kemoterapi neoajuvan adalah 23 pasien (76,6%) dan tidak respon 7 pasien (23,4%).
Kelompok pasien yang memberikan respon terhadap kemoterapi, 15 pasien ( 50%)
memiliki intensitas EGFR yang lemah. Pasien dengan tingkat ekstensif T3-T4 ,
mempunyai ekspresi EGFR lebih besar dibandingkan T1-T2 tumor.
Kesimpulan : Proporsi ekspresi EGFR pada kanker nasofaring di Indonesia sebesar 90
persen. Kemoterapi neoajuvan lebih respon pada tumor dengan ekspresi EGFR positif
dan intensitas EGFR yang lemah. Tumor dengan tingkat ekstensif yang lebih tinggi,
mempunyai ekspresi EGFR lebih tinggi.
ABSTRACTBackground: Neoadjuvan chemotherapy is one option of treatment for nasopharyngeal
cancer (NPC). The response of chemotherapy influenced by EGFR expression. EGFR
is important factor for the growth and tumors invasion. Purpose of the study is
compare of the EGFR expression level with response of neoadjuvan chemotherapy
and extensive level of the primary tumor. The methods is cross-sectional descriptive
study that assessment of response to neoadjuvan chemotherapy and extensive level of
the primary tumor. The NPC patients who have received chemotherapy is examined
of EGFR expression. Result of the study is the proportion of EGFR expression in NPC
for negative, positive and strong expression is 10%, 70%, and 20% respectively.
Patients who responses to neoadjuvan chemotherapy are 23 patients(76.6%) and
non-responses 7 patients (23.4%). The group patients who responses to chemotherapy,
15 patients (50%) have EGFR weak intensity. Patients with T3-T4 tumors (56,6%)
have EGFR expression is greater than T1-T2 tumors(44,4%).
Conclusion , The proportion of EGFR expression in NPC in Indonesia is 90 percent.
Neoajuvan chemotherapy is more response in tumors with positive EGFR expression
and weak intensity. Tumors with high extensive levels have higher EGFR
expression.;Background: Neoadjuvan chemotherapy is one option of treatment for nasopharyngeal
cancer (NPC). The response of chemotherapy influenced by EGFR expression. EGFR
is important factor for the growth and tumors invasion. Purpose of the study is
compare of the EGFR expression level with response of neoadjuvan chemotherapy
and extensive level of the primary tumor. The methods is cross-sectional descriptive
study that assessment of response to neoadjuvan chemotherapy and extensive level of
the primary tumor. The NPC patients who have received chemotherapy is examined
of EGFR expression. Result of the study is the proportion of EGFR expression in NPC
for negative, positive and strong expression is 10%, 70%, and 20% respectively.
Patients who responses to neoadjuvan chemotherapy are 23 patients(76.6%) and
non-responses 7 patients (23.4%). The group patients who responses to chemotherapy,
15 patients (50%) have EGFR weak intensity. Patients with T3-T4 tumors (56,6%)
have EGFR expression is greater than T1-T2 tumors(44,4%).
Conclusion , The proportion of EGFR expression in NPC in Indonesia is 90 percent.
Neoajuvan chemotherapy is more response in tumors with positive EGFR expression
and weak intensity. Tumors with high extensive levels have higher EGFR
expression.;Background: Neoadjuvan chemotherapy is one option of treatment for nasopharyngeal
cancer (NPC). The response of chemotherapy influenced by EGFR expression. EGFR
is important factor for the growth and tumors invasion. Purpose of the study is
compare of the EGFR expression level with response of neoadjuvan chemotherapy
and extensive level of the primary tumor. The methods is cross-sectional descriptive
study that assessment of response to neoadjuvan chemotherapy and extensive level of
the primary tumor. The NPC patients who have received chemotherapy is examined
of EGFR expression. Result of the study is the proportion of EGFR expression in NPC
for negative, positive and strong expression is 10%, 70%, and 20% respectively.
Patients who responses to neoadjuvan chemotherapy are 23 patients(76.6%) and
non-responses 7 patients (23.4%). The group patients who responses to chemotherapy,
15 patients (50%) have EGFR weak intensity. Patients with T3-T4 tumors (56,6%)
have EGFR expression is greater than T1-T2 tumors(44,4%).
Conclusion , The proportion of EGFR expression in NPC in Indonesia is 90 percent.
Neoajuvan chemotherapy is more response in tumors with positive EGFR expression
and weak intensity. Tumors with high extensive levels have higher EGFR
expression.;Background: Neoadjuvan chemotherapy is one option of treatment for nasopharyngeal
cancer (NPC). The response of chemotherapy influenced by EGFR expression. EGFR
is important factor for the growth and tumors invasion. Purpose of the study is
compare of the EGFR expression level with response of neoadjuvan chemotherapy
and extensive level of the primary tumor. The methods is cross-sectional descriptive
study that assessment of response to neoadjuvan chemotherapy and extensive level of
the primary tumor. The NPC patients who have received chemotherapy is examined
of EGFR expression. Result of the study is the proportion of EGFR expression in NPC
for negative, positive and strong expression is 10%, 70%, and 20% respectively.
Patients who responses to neoadjuvan chemotherapy are 23 patients(76.6%) and
non-responses 7 patients (23.4%). The group patients who responses to chemotherapy,
15 patients (50%) have EGFR weak intensity. Patients with T3-T4 tumors (56,6%)
have EGFR expression is greater than T1-T2 tumors(44,4%).
Conclusion , The proportion of EGFR expression in NPC in Indonesia is 90 percent.
Neoajuvan chemotherapy is more response in tumors with positive EGFR expression
and weak intensity. Tumors with high extensive levels have higher EGFR
expression.;Background: Neoadjuvan chemotherapy is one option of treatment for nasopharyngeal
cancer (NPC). The response of chemotherapy influenced by EGFR expression. EGFR
is important factor for the growth and tumors invasion. Purpose of the study is
compare of the EGFR expression level with response of neoadjuvan chemotherapy
and extensive level of the primary tumor. The methods is cross-sectional descriptive
study that assessment of response to neoadjuvan chemotherapy and extensive level of
the primary tumor. The NPC patients who have received chemotherapy is examined
of EGFR expression. Result of the study is the proportion of EGFR expression in NPC
for negative, positive and strong expression is 10%, 70%, and 20% respectively.
Patients who responses to neoadjuvan chemotherapy are 23 patients(76.6%) and
non-responses 7 patients (23.4%). The group patients who responses to chemotherapy,
15 patients (50%) have EGFR weak intensity. Patients with T3-T4 tumors (56,6%)
have EGFR expression is greater than T1-T2 tumors(44,4%).
Conclusion , The proportion of EGFR expression in NPC in Indonesia is 90 percent.
Neoajuvan chemotherapy is more response in tumors with positive EGFR expression
and weak intensity. Tumors with high extensive levels have higher EGFR
expression.;Background: Neoadjuvan chemotherapy is one option of treatment for nasopharyngeal
cancer (NPC). The response of chemotherapy influenced by EGFR expression. EGFR
is important factor for the growth and tumors invasion. Purpose of the study is
compare of the EGFR expression level with response of neoadjuvan chemotherapy
and extensive level of the primary tumor. The methods is cross-sectional descriptive
study that assessment of response to neoadjuvan chemotherapy and extensive level of
the primary tumor. The NPC patients who have received chemotherapy is examined
of EGFR expression. Result of the study is the proportion of EGFR expression in NPC
for negative, positive and strong expression is 10%, 70%, and 20% respectively.
Patients who responses to neoadjuvan chemotherapy are 23 patients(76.6%) and
non-responses 7 patients (23.4%). The group patients who responses to chemotherapy,
15 patients (50%) have EGFR weak intensity. Patients with T3-T4 tumors (56,6%)
have EGFR expression is greater than T1-T2 tumors(44,4%).
Conclusion , The proportion of EGFR expression in NPC in Indonesia is 90 percent.
Neoajuvan chemotherapy is more response in tumors with positive EGFR expression
and weak intensity. Tumors with high extensive levels have higher EGFR
expression.;Background: Neoadjuvan chemotherapy is one option of treatment for nasopharyngeal
cancer (NPC). The response of chemotherapy influenced by EGFR expression. EGFR
is important factor for the growth and tumors invasion. Purpose of the study is
compare of the EGFR expression level with response of neoadjuvan chemotherapy
and extensive level of the primary tumor. The methods is cross-sectional descriptive
study that assessment of response to neoadjuvan chemotherapy and extensive level of
the primary tumor. The NPC patients who have received chemotherapy is examined
of EGFR expression. Result of the study is the proportion of EGFR expression in NPC
for negative, positive and strong expression is 10%, 70%, and 20% respectively.
Patients who responses to neoadjuvan chemotherapy are 23 patients(76.6%) and
non-responses 7 patients (23.4%). The group patients who responses to chemotherapy,
15 patients (50%) have EGFR weak intensity. Patients with T3-T4 tumors (56,6%)
have EGFR expression is greater than T1-T2 tumors(44,4%).
Conclusion , The proportion of EGFR expression in NPC in Indonesia is 90 percent.
Neoajuvan chemotherapy is more response in tumors with positive EGFR expression
and weak intensity. Tumors with high extensive levels have higher EGFR
expression., Background: Neoadjuvan chemotherapy is one option of treatment for nasopharyngeal
cancer (NPC). The response of chemotherapy influenced by EGFR expression. EGFR
is important factor for the growth and tumors invasion. Purpose of the study is
compare of the EGFR expression level with response of neoadjuvan chemotherapy
and extensive level of the primary tumor. The methods is cross-sectional descriptive
study that assessment of response to neoadjuvan chemotherapy and extensive level of
the primary tumor. The NPC patients who have received chemotherapy is examined
of EGFR expression. Result of the study is the proportion of EGFR expression in NPC
for negative, positive and strong expression is 10%, 70%, and 20% respectively.
Patients who responses to neoadjuvan chemotherapy are 23 patients(76.6%) and
non-responses 7 patients (23.4%). The group patients who responses to chemotherapy,
15 patients (50%) have EGFR weak intensity. Patients with T3-T4 tumors (56,6%)
have EGFR expression is greater than T1-T2 tumors(44,4%).
Conclusion , The proportion of EGFR expression in NPC in Indonesia is 90 percent.
Neoajuvan chemotherapy is more response in tumors with positive EGFR expression
and weak intensity. Tumors with high extensive levels have higher EGFR
expression.]